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Abstract
Objectives: The US opioid medication epidemic has resulted in serious health consequences for 
patients. Formulary management tools adopted by payers, specifically prior authorization policies 
(PA), may lower rates of opioid medication abuse and overdose. We compared rates of opioid 
abuse and overdose among enrollees in plans that varied in their use of PA from High (required PA 
for 17–74 opioids), Low (required PA for 1 opioid), to No PA policies for opioid medications.
Study Design: Retrospective cohort study of patients initiating opioid treatment in Pennsylvania 
Medicaid from 2010 to 2012.
Methods: Generalized linear models with generalized estimating equations were employed to 
assess relationships between presence of PA policies and opioid medication abuse and overdose, as 
measured in Medicaid claims data, adjusting for demographics, comorbid health conditions, 
benzodiazepine/muscle relaxant use, and emergency department use.
Results: The study cohort included 297,634 enrollees, with a total of 382,828 opioid treatment 
episodes. Compared to plans with no PA, enrollees in High PA (Adjusted Rate Ratio [ARR]=0.89, 
95% CI=0.85–0.93, p<0.001) and Low PA plans (ARR=0.93, 95%CI=0.87–1.00, p=0.04) had 
lower rates of abuse. Enrollees in the Low PA plan had a lower rate of overdose than those within 
plans with No PA (ARR=0.75, 95% CI=0.59–0.95, p=0.02). High PA plan enrollees were also less 
likely than No PA enrollees to experience overdose, but this association was not statistically 
significant (ARR=0.88, 95% CI=0.76–1.02, p=0.08).
Conclusions: Enrollees within Medicaid plans that utilize PA policies appear to have lower rates 
of abuse and overdose following initiation of opioid medication treatment.
Précis:
Enrollees in Medicaid plans employing prior authorization policies for opioid medications may 
have lower rates of opioid medication abuse and overdose.
Keywords
Opioid overdose; opioid abuse; prior authorization; Medicaid
Introduction
The US opioid medication epidemic has led to serious effects on public health, including 
opioid-related overdoses and mortality.1,2 Perhaps the largest system-level investment in the 
US to address abuse and prevent overdose has been Prescription Drug Monitoring Programs,
3–5
 which have shown mixed results for protecting patient health.3,6,7 Another system-level 
intervention is a lock-in program, wherein patients who exceed filling pattern thresholds are 
limited to specific providers/pharmacies to receive future opioid medications,8 which 
programs have shown some promise for improving medication monitoring and reducing 
diversion.9 Formulary management tools may represent a valuable set of interventions 
payers can employ to control opioid medication consumption, deter shopping behaviors, and 
improve quality and safety.10
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One specific formulary management tool that may be used to address the opioid crisis is 
prior authorization (PA). PA is a requirement placed on some medications by payers that 
requires verification that the medication is necessary and/or patients meet medical criteria 
for use.11 An extensive body of literature has shown cost saving benefits of PA policies for a 
variety of medications (often expensive name brand drugs),12,13 but limited research has 
been conducted on their impact on patient-related opioid and quality of care outcomes.14–16 
PA policies applied in public or commercial health insurance plans frequently result in 
reductions in medication use,17– 20 but often this result is accomplished by placing 
administrative burdens on clinicians.21
Medicaid programs serving low-income populations have federally allowable copayments 
mandating minimal out-of-pocket costs that can be charged to enrollees.22 Medicaid 
programs are therefore particularly reliant on PA policies as opposed to other formulary 
management tools that use cost-sharing to influence demand. Research has shown 
approximately one-quarter of Medicaid patients who regularly use opioid medications (>90 
days) are engaged in problematic opioid consumption behaviors,23 and Medicaid enrollees 
on average receive more than double the total annual opioid dose compared to the privately 
insured.24 To date, 19 states’ Medicaid programs have required PA for long-acting opioids, 
and studies show these policies can reduce long-acting opioid fills.14‘16 The extent to which 
PA policies can help reduce the problematic opioid-related outcomes of abuse and drug 
overdose is unknown. We hypothesized enrollees within Medicaid fee-for service (FFS) 
programs and managed care plans employing PA policies for opioid medications would have 
lower rates of: (1) abuse and (2) opioid medication overdose compared to patients enrolled 
in Medicaid plans without PA. Understanding potential associations between PA and abuse 
and overdose may provide health systems and payers with an additional tool to address 
problematic opioid-related outcomes.
Methods
Design
This investigation was a retrospective cohort study that utilized Pennsylvania Medicaid data 
from 2010 to 2012. The Pennsylvania Medicaid program is among the largest in the US in 
both expenditures and enrollment, and Pennsylvania’s healthcare utilization and access25 
and statewide demographic profile (with the exception of lower rates of Hispanics)26 are 
similar to those seen across the nation. Pennsylvania has the 8th highest overdose rate in the 
US, and opioid prescribing rates are consistently above national averages.27,28 We obtained 
Pennsylvania Medicaid data directly from the Pennsylvania Department of Human Services 
(PADHS) for all FFS and managed care enrollees.
We used Medicaid enrollment data and pharmacy/medical claims to establish an analytic 
cohort of Medicaid enrollees who initiated a new opioid medication not used for addiction 
treatment (Appendix 1). We included patients in the study cohort that were between 18–64 
years of age, not dually eligible for Medicare (given we could not capture medication use for 
those >64 years/dually eligible), without previous cancer treatment, not in long-term care for 
≥90 days, and not receiving hospice services (as opioid use patterns would likely differ for 
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these groups). We identified the index opioid exposure event as patients’ first oral, 
transdermal, or submucosal opioid medication fill.
To identify new episodes of opioid medication treatment, we excluded individuals from the 
cohort that possessed a record of filling any opioid medication, had an opioid use disorder, 
or experienced an opioid medication overdose in the six months prior to the index opioid fill. 
This step in the cohort construction allowed us to create a “clean” baseline period for 
patients before they were exposed to opioid medications and potentially developed abuse or 
experienced overdose. Lapses in fills following the index fill greater than six months ended 
patients’ eligible treatment episodes. We selected a 6-month gap in fills to end the episode to 
be consistent with prior studies validating this approach in behavioral health populations.29 
We examined numbers of patient episodes by plan PA status, and no major differences were 
detected (results not shown). This study was designated exempt by the University of 
Pittsburgh Institutional Review Board.
Variables
Outcomes.—We identified opioid medication abuse following previously published 
approaches30,31 using International Classification of Diseases, 9th Edition (ICD-9)32 coding 
classifications and pharmacy claims. After the index fill, enrollees who had any code for an 
opioid use disorder (ICD9 304.0, 304.00, 304.01, 304.02, 304.03, 304.7, 304.70, 304.71, 
304.72, 304.73, 305.5, 305.50, 305.51, 305.52, 305.53) or opioid medication poisoning 
(ICD-9 965.00 [opium poisoning], 965.02 [methadone poisoning], 965.09 [opiate poisoning-
not elsewhere classified], E.850.1 [accidental methadone poisoning], and E.850.2 [accidental 
opioid poisoning- not elsewhere classified])33 and had any overlapping fill for a opioid pain 
medication were categorized as having abuse (no abuse=0, abuse=1).30,31 Patients meeting 
this definition of abuse have been observed to have both heightened overdose risk34 and to 
have serious behavioral, mental, and/or physical health problems.30,31 We recognize this 
definition of abuse does not match the Diagnostic and Statistical Manual for Mental 
Disorders; we chose to employ this term given its previous use in the literature.30,31
The opioid overdose indicator used in this analysis followed previously established methods 
for identifying prescription opioid overdose using International Classification of Disease, 9th 
edition (ICD-9)32 codes within claims data.33 The overdose indicator occurred after the 
index opioid fill, was comprised of opioid medication poisoning codes (ICD-9 965.00, 
965.02, 965.09, E.850.1, E.850.2), and was dichotomized (no overdose=0, overdose=1). 
These codes capture non-fatal and fatal overdose events resulting in hospitalization, 
emergency department visits, and /or other medical care. We do not capture overdose events 
outside of the healthcare system, which events may have largely been untreated within 
Pennsylvania given the limited and variable availability of naloxone to public safety and 
prehospital healthcare professionals during the study years. We acknowledge that abuse and 
overdose are both constructed using poisoning claims, and that there is some overlap 
between these measures; however, we chose this approach (i.e., not removing the poisoning 
codes from the abuse indicator) to remain consistent with the previous literature.
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PA indicator.—Specification of plans in Pennsylvania Medicaid with PA took place in 
partnership with the Bureau of Managed Care within PADHS. Officials from the Bureau 
provided FFS PA information as well as contacted all managed care plans (N=8) via email 
requesting historical formulary medication management policy information between January 
1, 2010 and December 31, 2012. Qualitative responses were transferred into a data tracking 
template. Given the variation in use of PA across plans in our study data, we followed an 
ordinal classification approach for categorization of policies similar to those previously 
employed in the literature.35 One insurance plan was labeled Low PA (required PA for 1 
opioid); 2 plans were labeled High PA (required PA for 17–74 opioids), and 6 plans were 
labeled No PA based on number of generic, name brand, and combination product 
medications subjected to PA (Table 1). PA policies were active before or on the first day of 
our study observation period (1/1/2010), thus limiting our ability to compare differences 
between plans across time. We therefore conducted a cross-sectional comparison of 
enrollees across plan types.
Covariates—Covariates were measured in the enrollees’ baseline periods. Demographic 
covariates included in the model were age (18–29, 30–39, 40–49, 50–64 years), sex, race/
ethnicity (white, black, Hispanic, other), Medicaid eligibility category (General Assistance, 
Supplemental Security Income, Temporary Assistance for Needy Families), Medicaid plan 
type (fee-for- service, managed care organization), and urban/rural county of residence 
(coded using RuralUrban Continuum Codes36,37).
We likewise included measures of comorbidity in the models, which were also measured at 
baseline. Specific comorbidities included: alcohol use disorders (abuse/dependence), non-
opioid drug use disorders (abuse/dependence [e.g., cocaine, marijuana] not including NEC 
codes [i.e., Not Elsewhere Classified], which clinicians may have used in lieu of opioid use 
disorder codes), several indicators for mental health disorders (adjustment, anxiety, mood, 
personality, miscellaneous), separate indicators for pain diagnoses (back, neck, arthritis/
joint, headache/migraine), and HIV/AIDS.38 We included in the model a modified 
Elixhauser comorbidity index, an indicator that used ICD codes to measure patient 
comorbidity within administrative claims data from hospitals and physician services. This 
indicator was modified by removing comorbidities described above that we included as 
individual covariates. Emergency department use was also included in the model (ED; ≥1 
visit[s]=1, <1 visit=0).
We included morphine milligram equivalents (MME) following the index fill but before the 
occurrence of abuse or overdose. MME was constructed by converting total within-episode 
opioid supply into morphine equivalents, dividing by days supplied, and coding into 4 levels: 
≥100 MME/day, 50-<100 MME/day, 20-<50 MME/day, <20 MME/day.39 Indicators of 
medication use that are known correlates with abuse/overdose were also added as covariates 
in the model, which included any use of benzodiazepines and muscle relaxants in the 
baseline period. Covariates were all categorical with the exception of the Elixhauser index, 
which was a count indicator, and age, which was ordinal.
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Analyses
With the exception of descriptive demographic characteristics that were calculated at the 
person-level for patients enrolled in the 3 PA plan types, analyses for this study were 
conducted at the episode-level. Our modeling strategy needed to account for two features of 
our data: heterogeneity in the duration of opioid use across episodes and some enrollees 
having multiple episodes. The importance of accounting for episode-level events for 
individual enrollees is based on the dynamic nature of patient behaviors and health status 
across time, which can alter an individual’s risk. We therefore employed generalized linear 
models with generalized estimating equations (GEE) using log link function and Poisson 
distribution where follow-up length (day) was treated as offset in the model, and the 
exchangeable covariance structure was employed to account for standard error correlation. 
These models therefore were able to account for greater exposure to opioids and PA policies 
within episode and greater numbers of episodes. These models were applied to examine the 
association between the outcome variables of opioid medication (1) abuse and (2) overdose 
and the predictor variable of PA adjusted for all covariates described above. We also report 
abuse and overdose rates with 95% confidence intervals by PA type adjusted for all 
covariates and offset log length of episode. All analyses were conducted with SAS 9.4.40
In an alternative model specification, we estimated both the abuse and overdose outcome 
analyses using a propensity score matching approach wherein we matched individuals in the 
High and Low PA plans to those in No PA plans. Results showed no substantive differences; 
therefore, we chose to present the adjusted GEE results instead of the matched sample for 
the purpose of simplicity and to maximize our sample size included in the analyses.
Results
The analytic cohort included 297,634 individual plan enrollees, with a total of 382,828 
opioid treatment episodes. Enrollees within the cohort typically had multiple opioid 
treatment episodes, with most patients having an average of 2 episodes (median=1; results 
not shown). Table 2 presents descriptive patient-level demographic and episode-level health 
and medication use characteristics. The largest proportions of patients were 18–29 years of 
age (n=140,876; 47.3%) and were female (n=212,209; 71.3%). The largest proportional 
differences among PA plans were for race and rural/urban living location. White enrollees 
were most prominent in High PA plans (77.2%, n=79,965), and Black (47.9%, n=15,950) 
and Hispanic (31.2%, n=10,386) enrollees were most prominent in the Low PA plan. Most 
Low (99.9%; n=33,226) and No PA (95.1%; n=152,913) enrollees lived in urban locations 
compared to 63.7% (n=65,948) of High PA plan enrollees.
The most common level of opioid consumption within episodes (60.9–68.6%) was 20–49.9 
MMEs/day following the index opioid fill. Unadjusted rate of abuse within episodes was 
3.46 for High PA plans, 2.36 for the Low PA plan, and 3.39 for the No PA plans after the 
index opioid medication fill. Unadjusted rate of overdose in episodes was 0.26 in High PA 
plans, 0.19 for the Low PA plan, and 0.29 in No PA plans after the index fill (Table 3).
Results of the GEE analyses adjusted for demographic and health status differences across 
plan types demonstrated individuals in High PA plans were 11% less likely to develop 
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opioid medication abuse after their index opioid medication fill compared to those within 
plans with No PA (95% CI=0.85–0.93, p<0.001). Enrollment in the Low PA plan was also 
associated with a 7% lower rate of developing opioid medication abuse after the opioid 
medication index fill (95% CI=0.87–1.00, p=0.04) relative to No PA. In terms of the 
relationship between PA and overdose, enrollment in the Low PA plan was associated with a 
25% lower rate of experiencing an overdose following the index opioid medication fill (95% 
CI=0.59–0.95, p=0.02). There was a non-significant 12% reduction in (95% CI=0.76–1.02, 
p=0.08) in overdose for enrollees in High PA plans. We recognize that the High PA plans 
had the highest unadjusted rate of abuse, but after adjustment, the No PA plan was the 
highest. To identify which set of covariates influenced this change, we re-estimated our 
model adding blocks of variables to the model in a stepwise fashion (e.g., block 1=abuse, 
overdose, and MME; block 2=demographics; block 3=mental/behavioral health and co-
occurring health conditions [i.e., pain, Elixhauser Index]). Results showed adding the 
demographic block resulted in the change. We also re-estimated the GEE analyses without 
the MME covariate to examine its influence on model outcomes. The magnitude/direction of 
all effects were unchanged removing MME.
Table 5 reports adjusted rates based on the GEE analyses for abuse and overdose per person 
days (where 452.1 [SD=299.2] was the average number of per person follow-up days for 
subjects in the cohort). The adjusted rates of abuse were 2.49% for High PA plans, 2.58% 
for the Low PA plan, and 2.76% for No PA plans per average person days. The adjusted rate 
of overdose was 0.21% for High PA plans, 0.17% for the Low PA plan, and 0.23% for No 
PA plans per average person days.
Discussion
The opioid medication epidemic has brought to the forefront of healthcare practice and 
policy the need to identify and intervene with patients engaged in abuse and at-risk for 
overdose. Policy-level efforts that limit access to opioid medications and influence patient/
prescriber behaviors have the potential to make an important impact for reducing negative 
patient outcomes. We analyzed data from Medicaid enrollees who developed opioid pain 
medication abuse or experienced overdose after initiating opioid treatment who were within 
plans that operated PA policies compared to plans that did not. Our findings showed a 
minority of plans implemented PA policies (3/9 plans), and there was substantial variation in 
the number of medications within plans subjected to PA policies (range=1–74).
Enrollment in High and Low PA plans was associated with modestly lower adjusted rates of 
opioid medication abuse, and enrollment in the Low PA plan was associated with lower 
adjusted rates of overdose. These results are consistent with previously published studies 
that have examined the effect of PA on opioid medication fills. Specifically, our findings that 
PA was associated with 7 to 11% (<0.05) lower rates for abuse and 12 (p=0.08) to 25% 
(p=0.02) lower rates for overdose are consistent with studies that have reported 8 to 19% 
reductions in long- acting opioid medication fills among enrollees in plans that utilized PA 
policies.14,15
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A central point of importance for our findings is they advance previous studies reporting 
reductions in long-acting opioid medication fills, which outcome metric has limited ability 
to differentiate between patients with problematic use and those who may benefit from 
opioid medications. Assessing only fills as an outcome also cannot disentangle patient and 
prescriber behavior. Accordingly—evaluating benefit of PA policies by changes in abuse and 
overdose more effectively discriminates reductions in potential repercussions of opioid use
—perhaps demonstrating an outcome especially relevant to combatting the national opioid 
epidemic. Further, reductions in abuse, for example, could have valuable ramifications for 
health systems, payers, and prescriber stakeholders as patients with opioid use disorders 
have higher healthcare needs, utilization, and costs.41
Future research should seek to extend our findings by examining the effect of PA within an 
analytical framework capable of examining both within and between group differences over 
time. Such studies should seek account for legitimate pain management needs of patients. In 
particular, while abuse and overdose are both important outcomes for patient safety and 
health, future studies should examine potentially unintended consequences of PA plans on 
patients, such as under-treatment of painful conditions42 or transition to heroin use.2 If 
future research continues to provide support for PA, broader implementation of these 
policies may necessitate streamlined and automated approaches to minimize disruption to 
medical/pharmacy workflow.21
Limitations
These findings should be viewed in light of certain limitations. First, while we recognize 
strengths of our study include possessing actual PA information from Medicaid plans, 
having complete FFS and managed care data, and Pennsylvania being similar to other 
programs in the nation with respect to healthcare utilization, access,25 and demographics;26 
it nonetheless represents one state in the US. Second, the last year for our data was 2012, 
and some analyses have shown reductions in opioid abuse and diversion in more recent 
years.43 Furthermore, the larger Medicaid landscape has evolved since this date, including 
the expansion of Medicaid through the Affordable Care Act in Pennsylvania as in many 
other states. Studies conducted with more recent data may yield different estimates as a 
result of these changes. PADHS also recently implemented additional restrictions on 
opioids,44,45 that may yield even greater benefit. However, these policies went into effect 
after our study period ended so we were unable to evaluate them. Third, we used a simple 
and straightforward approach to categorizing PA schemes (High, Low, and No based on the 
number of products subject to PA). It is possible our data collection method did not capture 
other aspects of these policies such as the ease of use that may influence prescribing 
behavior. It is also possible that we did not capture information on all plan features or 
policies that may influence opioid prescribing and use. In light of this, we recognize our 
characterization of the policies may not capture the full range of interventions plans may 
have had in place. We note, however, that enrollees with evidence of opioid medication 
misuse have an equal possibility of enrollment in the state Medicaid agency operated lock-in 
program. Fourth, while the abuse measure is one of the more common and valid indicators in 
the field,46 it has the potential to misclassify individuals engaged legitimate use of opioids. 
Moreover, while we have been able to adjust for a number of patient-level characteristics in 
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our analyses that could have introduced bias into our findings, other individual- level factors 
and regional variation in our outcomes could have influenced study outcomes. Future 
research should seek to employ quasi-experimental designs with comparison groups, such as 
difference-in-differences analyses, to help better understand the impact of PA. Last, we 
recognize opioid use disorders are likely under-coded within claims data47 and claims data 
do not account for cash payments to prescribers/pharmacies, which could influence observed 
associations were these data available.48
Conclusion
This study examined associations between PA requirements and developing abuse or 
experiencing an opioid medication overdose following an index opioid medication fill for 
Medicaid enrollees. These findings extend previous research by demonstrating improved 
outcomes among patients within PA plans in terms of lower rates of abuse and overdose. 
Future research should seek to extend these findings within more rigorous causal designs/
analyses and among other Medicaid and commercial payer data to continue building 
evidence for PA policies reducing problematic opioid behaviors and consequences.
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Take-Away Points:
Health insurance payers can implement policies to help curb the opioid epidemic. This 
retrospective cohort study of Pennsylvania Medicaid data examined associations between 
Medicaid plans that utilized prior authorization policies for opioid medications and 
enrollees: (1) developing opioid medication abuse or (2) experiencing overdose.
– Enrollees within plans that subjected opioid medications to prior 
authorization policies had lower rates of opioid medication abuse and 
overdose after initiating opioid medication treatment.
– Future research should work to extend these findings in order to support 
systematic and large scale implementation of prior authorization policies for 
opioid medications.
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Table 1.
Summary Description of Prior Authorization by Plan
Plan
N of medications subject
to prior authorization a
Earliest date of
implementation b
Low prior authorization plan
 Plan A 1c 1/2010
High prior authorization plans
 Plan B 17 <2010
 Plan C 74 <2010
No Prior authorization plans
 Plans D-I None Not applicable
aNumber (N) of medications includes generic, name brand, and combination products
bdate represents first date reported for any medication subjected to PA requirement
c
the single medication was OxyContin.
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Table 2.
Demographic, Behavioral Health Characteristics, and Comorbidities by Level of Prior Authorization
Characteristics Total n (%)
High Prior
Authorization
n (%)
Low prior
authorization
n (%)
No prior
authorization
n (%)
Patient Level a 297,634 (100.0) 103,587 (34.8) 33,270 (11.2) 160,777 (54.0)
Demographics
Age, y
 18–29 140,876 (47.3) 50,946 (49.2) 13,619 (40.9) 76,311 (47.5)
 30–39 66,258 (22.3) 23,366 (22.6) 7,188 (21.6) 35,704 (22.2)
 40–49 47,584 (16.0) 15,696 (15.2) 6,130 (18.4) 25,758 (16.0)
 50–64 42,916 (14.4) 13,579 (13.1) 6,333 (19.0) 23,004 (14.3)
Female 212,209 (71.3) 73,891 (71.3) 23,568 (70.8) 114,750 (71.4)
Race
 White 167,175 (56.2) 79,965 (77.2) 5,418 (16.3) 81,792 (50.9)
 Black 83,874 (28.2) 14,641 (14.1) 15,950 (47.9) 53,283 (33.1)
 Hispanic 35,885 (12.1) 6,416 (6.2) 10,386 (31.2) 19,083 (11.9)
 Other 10,700 (3.6) 2,565 (2.5) 1,516 (4.6) 6,619 (4.1)
Urban 252,087 (84.7) 65,948 (63.7) 33,226 (99.9) 152,913 (95.1)
Type of eligibility
 GA 32,256 (10.8) 9,162 (8.8) 5,075 (15.3) 18,019 (11.2)
 SSI 86,785 (29.2) 31,167 (30.1) 10,702 (32.2) 44,916 (27.9)
 TANF 178,593 (60.0) 63,258 (61.1) 17,493 (52.6) 97,842 (60.9)
Medicaid region
 Region 1 54,475 (18.3) 13,233 (12.8) 112 (0.3) 41,130 (25.6)
 Region 2 38,602 (13.0) 36,791 (35.5) 74 (0.2) 1,737 (1.1)
 Region 3 26,861 (9.0) 23,346 (22.5) 8 (0.0) 3,507 (2.2)
 Region 4 104,890 (35.2) 8,780 (8.5) 33,044 (99.3) 63,066 (39.2)
 Region 5 72,806 (24.5) 21,437 (20.7) 32 (0.1) 51,337 (31.9)
Episode-level b (N=382,828)
Behavioral and Mental Health
Alcohol use disorder 9,973 (2.6) 3,342 (2.6) 978 (2.3) 5,653 (2.7)
Drug use disorder 8,795 (2.3) 2,383 (1.8) 1,058(2.5) 5,354 (2.5)
Adjustment disorders 8,509 (2.2) 3,274 (2.5) 810 (1.9) 4,425 (2.1)
Anxiety disorders 39,604 (10.4) 13,958 (10.8) 4,102 (9.5) 21,544 (10.2)
Mood disorders 84,437 (22.1) 28,332 (21.9) 10,970 (25.5) 45,135 (21.4)
Personality disorders 2,034 (0.5) 847 (0.7) 109 (0.3) 1,078 (0.5)
Miscellaneous mental health disorders 12,082 (3.2) 3,957 (3.1) 1,522 (3.5) 6,603 (3.1)
Painful Conditions and Healthcare Utilization
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Characteristics Total n (%)
High Prior
Authorization
n (%)
Low prior
authorization
n (%)
No prior
authorization
n (%)
Back pain 67,346 (17.6) 22,971 (17.8) 8,294 (19.3) 36,081 (17.1)
Neck pain 23,822 (6.2) 8,246 (6.4) 2,738 (6.4) 12,838 (6.1)
HIV/AIDS 3,525 (0.9) 495 (0.4) 878 (2.0) 2,152 (1.0)
Arthritis/joint pain 76,691 (20.0) 25,312 (19.6) 9,468 (22.0) 41,911 (19.9)
Headache/migraine pain 15,514 (4.1) 5,722 (4.4) 1,380 (3.2) 8,412 (4.0)
ED visit 180,045 (47.0) 59,237 (45.8) 20,528 (47.7) 100,280 (47.6)
Medication Use
Benzodiazepine use 55,986 (14.6) 18,287 (14.2) 7,317 (17.0) 30,383 (14.4)
Muscle relaxant use 36,597 (9.6) 12,555 (9.7) 4,484 (10.4) 19,558 (9.3)
Comorbidity
Elixhauser indexc 1.12 (1.62) 1.07 (1.57) 1.42 (1.84) 1.09 (1.59)
a
Measured at the person level, N=297,634;
b
Measured at the event-level, N=382,828;
c
mean (standard deviation)
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Table 3.
Post-Index Fill Unadjusted Rates of Abuse, a Overdose, a and Morphine Milligram Equivalents (MME) b by 
Prior Authorization Type c
Indicator
No prior
authorization
Low Prior
Authorization
High Prior
Authorization
Abuse 3.39 2.36 3.46
Overdose 0.29 0.19 0.26
MME/Day
 <20 17.0 21.8 15.4
 20–49.9 67.9 60.9 68.6
 50–99.9 12.6 14.8 13.4
 >100 2.5 2.6 2.6
aAbuse and overdose rates are calculated after the index fill.
b
Morphine milligram equivalents are calculated after the index fill and before abuse and overdose occur.
cAnalyses conducted at the episode-level.
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Table 4.
Generalized Estimating Equation Estimates for Opioid Abuse a and Overdose b Adjusted for All Covariates 
and Offset by Log Length of Episode c
Abuse Overdose
Predictor ARR (95% CI) d p e ARR (95% CI) p
Prior authorization (reference =No prior authorization)
Low 0.93 (0.87–1.00) 0.04 0.75 (0.59–0.95) 0.02
High 0.89 (0.85–0.93) <.001 0.88 (0.76–1.02) 0.08
Categorical MME f, MME/day (reference=<20)
20–49.9 1.05 (1.00–1.10) 0.06 0.97 (0.82–1.16) 0.77
50–99.9 1.17 (1.10–1.25) <.001 1.42 (1.15–1.75) 0.001
≥100 2.12 (1.97–2.28) <.001 2.58 (2.04–3.27) <.001
Demographics
Race (reference=Other)
 White 2.12 (1.86–2.42) <.001 1.41 (0.92–2.16) 0.11
 Black 0.92 (0.80–1.05) 0.21 0.90 (0.58–1.40) 0.65
 Hispanic 0.81 (0.70–0.93) 0.004 0.62 (0.38–1.01) 0.06
Female 0.70 (0.67–0.73) <.001 0.87 (0.75–1.00) 0.04
Age, y 0.86 (0.85–0.88) <.001 0.99 (0.93–1.05) 0.73
Urban 1.13 (1.07–1.19) <.001 1.33 (1.10–1.62) 0.004
Eligibility type (reference=Temporary Assistance for Needy Families)
 General assistance 1.77 (1.67–1.86) <.001 1.58 (1.28–1.94) <.001
 Supplemental Security Income 0.94 (0.90–0.98) 0.005 1.26 (1.08–1.48) 0.004
Mental/behavioral health
Alcohol abuse/dependence 1.42 (1.32–1.54) <.001 1.47 (1.14–1.90) 0.003
Non-opioid drug use disorder 2.08 (1.92–2.24) <.001 1.26 (0.92–1.71) 0.15
Adjustment disorders 1.12 (1.01–1.23) 0.03 1.11 (0.81–1.53) 0.51
Anxiety disorders 1.21 (1.16–1.27) <.001 1.26 (1.07–1.48) 0.005
Mood disorders 1.41 (1.35–1.48) <.001 1.29 (1.12–1.50) <.001
Personality disorders 0.97 (0.83–1.13) 0.69 0.87 (0.50–1.52) 0.63
Miscellaneous mental health disorders 1.05 (0.96–1.14) 0.31 1.01 (0.74–1.38) 0.95
Painful conditions and healthcare utilization
Back pain 1.26 (1.21–1.31) <.001 1.29 (1.12–1.49) <.001
Neck pain 1.06 (1.00–1.12) 0.04 1.17 (0.98–1.41) 0.08
HIV/AIDS 1.68 (1.45–1.94) <.001 1.04 (0.59–1.85) 0.89
Arthritis/joint pain 0.95 (0.91–0.99) 0.01 1.13 (0.99–1.30) 0.07
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Abuse Overdose
Predictor ARR (95% CI) d p e ARR (95% CI) p
Headache/migraine pain 0.95 (0.88–1.02) 0.17 0.99 (0.77–1.28) 0.96
Health services/comorbidity
ED visit 1.28 (1.23–1.33) <.001 1.43 (1.25–1.63) <.001
Medication use
Benzodiazepine use 1.73 (1.66–1.81) <.001 2.12 (1.82–2.46) <.001
Muscle relaxant use 1.18 (1.13–1.24) <.001 1.40 (1.20–1.64) <.001
Comorbidity
Elixhauser comorbidity index 0.94 (0.92–0.95) <.001 1.06 (1.02–1.10) 0.004
aNumber of abuse events is 12,631
b
number of overdose events is 1,024
cAnalyses conducted at the episode-level.
dARR=adjusted rate ratio, CI=confidence interval;
ep=probability value;
f
MME/day observed before abuse or overdose.
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Table 5.
Abuse and Overdose Rate with 95% Confidence Interval by Prior Authorization Adjusted Rate Ratio for All 
Covariates and Offset by Log Length of Episode (Day) a, b
Indicator ARR b (95% CI)
Abuse
 High PA 2.49 (2.35–2.62)
 Low PA 2.58 (2.40–2.76)
 No PA 2.76 (2.67–2.89)
Overdose
 High PA 0.21 (0.17–0.25)
 Low PA 0.17 (0.14–0.22)
 No PA 0.23 (0.20–0.27)
aAverage number of follow-up days for subjects=452.1 (SD=299.2). ARR=Adjusted Rate Ratio.
bAnalyses conducted at the episode-level.
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